![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BLCAP |
Gene summary for BLCAP |
![]() |
Gene information | Species | Human | Gene symbol | BLCAP | Gene ID | 10904 |
Gene name | BLCAP apoptosis inducing factor | |
Gene Alias | BC10 | |
Cytomap | 20q11.23 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | P62952 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10904 | BLCAP | ATC3 | Human | Thyroid | ATC | 2.23e-02 | 5.74e-02 | 0.338 |
10904 | BLCAP | ATC4 | Human | Thyroid | ATC | 3.95e-30 | 5.66e-01 | 0.34 |
10904 | BLCAP | ATC5 | Human | Thyroid | ATC | 1.61e-26 | 3.44e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
GO:0022411112 | Skin | cSCC | cellular component disassembly | 201/4864 | 443/18723 | 4.09e-19 | 5.69e-17 | 201 |
GO:0022411113 | Thyroid | PTC | cellular component disassembly | 232/5968 | 443/18723 | 1.36e-19 | 1.75e-17 | 232 |
GO:002241124 | Thyroid | ATC | cellular component disassembly | 248/6293 | 443/18723 | 1.34e-22 | 3.69e-20 | 248 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BLCAP | SNV | Missense_Mutation | c.118N>T | p.Arg40Trp | p.R40W | P62952 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
BLCAP | SNV | Missense_Mutation | novel | c.236N>T | p.Ala79Val | p.A79V | P62952 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.491) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BLCAP | SNV | Missense_Mutation | novel | c.236N>T | p.Ala79Val | p.A79V | P62952 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.491) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BLCAP | SNV | Missense_Mutation | c.233C>T | p.Ser78Leu | p.S78L | P62952 | protein_coding | tolerated_low_confidence(0.18) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
BLCAP | SNV | Missense_Mutation | novel | c.221C>G | p.Pro74Arg | p.P74R | P62952 | protein_coding | tolerated_low_confidence(0.46) | benign(0.007) | TCGA-AX-A3FV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BLCAP | SNV | Missense_Mutation | c.84C>A | p.Phe28Leu | p.F28L | P62952 | protein_coding | tolerated(0.2) | probably_damaging(0.992) | TCGA-66-2778-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
BLCAP | SNV | Missense_Mutation | novel | c.250N>A | p.Val84Ile | p.V84I | P62952 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-YL-A8SR-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
BLCAP | SNV | Missense_Mutation | c.233N>T | p.Ser78Leu | p.S78L | P62952 | protein_coding | tolerated_low_confidence(0.18) | benign(0.007) | TCGA-D7-A4YU-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |